当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Axillary evaluation and lymphedema in women with ductal carcinoma in situ.

Axillary evaluation and lymphedema in women with ductal carcinoma in situ.

Abstract：

:Axillary evaluation in women with ductal carcinoma in situ (DCIS) is increasing; however, this may introduce additional morbidity with unclear benefit. Our objective was to examine the morbidity and mortality associated with axillary evaluation in DCIS. We conducted a retrospective cohort study of 10,504 women aged 65-90 years with DCIS who underwent breast conserving surgery between 2002 and 2012 using SEER-Medicare database. Patients were categorized by receipt of axillary evaluation with either sentinel lymph node biopsy (SLNB) or axillary node dissection (ALND). We determined the incidence of lymphedema treatment as defined by diagnostic and procedural codes, as well as 10-year breast cancer-specific and all-cause mortality. 18.3 % of those treated with BCS and 69.4 % of those treated with mastectomy had an axillary evaluation. One year after treatment, 8.2 % of women who had an axillary evaluation developed lymphedema, compared to 5.9 % of those who did not. In a multivariable Cox proportional hazard model, the incidence of lymphedema was higher among those who underwent axillary evaluation (HR 1.22, 95 % CI 1.04-1.45). Overall 10-year breast cancer-specific survival was similar between both groups (HR 0.83, 95 % CI 0.40-1.74). Only 44 (0.40 %) women died of breast cancer; receipt of axillary evaluation did not alter overall survival. Axillary evaluation is commonly performed in women with DCIS, especially those undergoing mastectomy. However, women who receive an axillary evaluation have higher rates of lymphedema, without breast cancer-specific or overall survival benefit. Efforts should be made to determine the population of women with DCIS who benefit from this procedure.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Coromilas EJ,Wright JD,Huang Y,Feldman S,Neugut AI,Hillyer GC,Chen L,Hershman DL

doi

10.1007/s10549-016-3890-0

subject

Has Abstract

pub_date

2016-07-01 00:00:00

pages

373-84

issue

2

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-016-3890-0

journal_volume

158

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels.

    abstract：:In contrast to deoxyribose or arabinose containing nucleoside analogs that are currently established for cancer therapeutics, 8-chloro-adenosine (8-Cl-Ado) possesses a ribose sugar. This unique nucleoside analog is RNA-directed and is in a phase I clinical trial for hematological malignancies. RNA-directed therapies a...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0481-3

    authors： Stellrecht CM,Ayres M,Arya R,Gandhi V

    更新日期：2010-06-01 00:00:00

  • Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.

    abstract：:The anti-estrogenic effect of tamoxifen is suggested to be mainly attributable to its metabolite (Z)-endoxifen, and a minimum therapeutic threshold for (Z)-endoxifen in serum has been proposed. The objective of this research was to establish the relationship between dried blood spot (DBS) and serum concentrations of t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2999-2

    authors： Jager NG,Rosing H,Schellens JH,Beijnen JH,Linn SC

    更新日期：2014-07-01 00:00:00

  • Association between persistence with mammography screening and stage at diagnosis among elderly women diagnosed with breast cancer.

    abstract：:Previous studies on the association between mammography screening and stage at breast cancer (BC) diagnosis have limitations because they did not analyze persistence with mammography screening and did not distinguish screening from diagnostic mammograms. The objective of this study is to determine the association betw...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3204-3

    authors： Vyas A,Madhavan S,Sambamoorthi U

    更新日期：2014-12-01 00:00:00

  • Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

    abstract：:The mutation pattern of breast cancer molecular subtypes is incompletely understood. The purpose of this study was to identify mutations in genes that may be targeted with currently available investigational drugs in the three major breast cancer subtypes (ER+/HER2-, HER2+, and Triple Negative). We extracted DNA from ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2035-3

    authors： Santarpia L,Qi Y,Stemke-Hale K,Wang B,Young EJ,Booser DJ,Holmes FA,O'Shaughnessy J,Hellerstedt B,Pippen J,Vidaurre T,Gomez H,Valero V,Hortobagyi GN,Symmans WF,Bottai G,Di Leo A,Gonzalez-Angulo AM,Pusztai L

    更新日期：2012-07-01 00:00:00

  • Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?

    abstract：PURPOSE:To investigate and compare the effects of mobile health (mHealth) and pedometer with conventional exercise program using a brochure on physical function and quality of life (QOL). METHODS:The study was a prospective, quasi-randomized multicenter trial where 356 patients whose cancer treatment had been terminat...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-016-4065-8

    authors： Uhm KE,Yoo JS,Chung SH,Lee JD,Lee I,Kim JI,Lee SK,Nam SJ,Park YH,Lee JY,Hwang JH

    更新日期：2017-02-01 00:00:00

  • Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.

    abstract：:Tumour hypoxia, being widespread in solid tumours, is related to an increased risk of invasion and metastasis as well as to resistance to chemotherapy and radiotherapy. Hypoxia-inducible factor-1alpha (HIF-1alpha) has emerged as the key regulator of the cellular response to hypoxia. In primary breast cancers, HIF-1alp...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9589-5

    authors： Smollich M,Götte M,Kersting C,Fischgräbe J,Kiesel L,Wülfing P

    更新日期：2008-03-01 00:00:00

  • Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast.

    abstract：:Following mastectomy, patients with operable breast cancer underwent postoperative irradiation of the chest wall and regional lymph nodes. They were then assigned at random to receive no further therapy, ovarian irradiation (2000 rad in five days) or ovarian irradiation in the same dosage plus prednisone, 7.5 mg daily...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01855127

    authors： Meakin JW,Allt WE,Beale FA,Bush RS,Clark RM,Fitzpatrick PJ,Hawkins NV,Jenkin RD,Pringle JF,Reid JG

    更新日期：1983-01-01 00:00:00

  • Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.

    abstract：PURPOSE:Studies of the etiology of inflammatory breast cancer (IBC), a rare but aggressive breast cancer, have been hampered by limited risk factor information. We extend previous studies by evaluating a broader range of risk factors. METHODS:Between 2009 and 2015, we conducted a case-control study of IBC at six cente...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05864-3

    authors： Schairer C,Hablas A,Eldein IAS,Gaafar R,Rais H,Mezlini A,Ayed FB,Ayoub WB,Benider A,Tahri A,Khouchani M,Aboulazm D,Karkouri M,Eissa S,Bastawisy AE,Yehia M,Gadalla SM,Swain SM,Merajver SD,Brown LM,Pfeiffer RM,Sol

    更新日期：2020-11-01 00:00:00

  • Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

    abstract：:Familial aggregations of breast/ovarian cancer cases frequently depend on BRCA1/2 pathogenic mutations. Here we counselled 120 Italian breast/ovarian cancer families and selected 73 probands for BRCA1/2 mutation screening. Through this analysis we defined the prevalence of BRCA1/2 pathogenic mutations occurring in Ita...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9225-9

    authors： Giannini G,Capalbo C,Ristori E,Ricevuto E,Sidoni T,Buffone A,Cortesi E,Marchetti P,Scambia G,Tomao S,Rinaldi C,Zani M,Ferraro S,Frati L,Screpanti I,Gulino A

    更新日期：2006-11-01 00:00:00

  • Transforming growth factor-beta in breast cancer: a working hypothesis.

    abstract：:Transforming Growth Factor-beta (TGF beta) is the most potent known inhibitor of the progression of normal mammary epithelial cells through the cell cycle. During the early stages of breast cancer development, the transformed epithelial cells appear to still be sensitive to TGF beta-mediated growth arrest, and TGF bet...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1005865812918

    authors： Reiss M,Barcellos-Hoff MH

    更新日期：1997-08-01 00:00:00

  • Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.

    abstract：:Obesity is associated with an increased risk of breast cancer (BC) and poorer outcome. We assessed the impact of body mass index (BMI) on pathological complete response (pCR), disease-free (DFS), and overall survival (OS), according to BC subtypes in patients with primary BC treated with neoadjuvant chemotherapy. 8,87...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3287-5

    authors： Fontanella C,Lederer B,Gade S,Vanoppen M,Blohmer JU,Costa SD,Denkert C,Eidtmann H,Gerber B,Hanusch C,Hilfrich J,Huober J,Schneeweiss A,Paepke S,Jackisch C,Mehta K,Nekljudova V,Untch M,Neven P,von Minckwitz G,Loibl

    更新日期：2015-02-01 00:00:00

  • Participation and satisfaction with surgical treatment decision-making in breast cancer among Chinese women.

    abstract：PURPOSE:To report Chinese women's preferred and perceived participation in breast cancer treatment decision making (TDM), describe influences on women's participation preference and participation congruence (PC) (correspondence between preferred and actual amount of participation in TDM), and explore subsequent satisfa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/A:1024568732213

    authors： Lam W,Fielding R,Chan M,Chow L,Ho E

    更新日期：2003-07-01 00:00:00

  • Association of RAD51C germline mutations with breast cancer among Bahamians.

    abstract：PURPOSE:RAD51C is known as an ovarian cancer gene; however, its role in breast cancer susceptibility is less clear. As part of a larger study, we assessed the role of germline RAD51C mutations in breast cancer development. METHODS:We studied 387 unselected, BRCA1- and BRCA2-negative, Bahamian breast cancer cases and 6...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05872-3

    authors： Bagherzadeh M,Szymiczek A,Donenberg T,Butler R,Hurley J,Narod SA,Akbari MR

    更新日期：2020-11-01 00:00:00

  • Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy.

    abstract：:Metastatic breast cancer is a systemic disease. However, certain subsets of patients, such as those with oligometastatic breast cancer (OMBC), have long-term survival prospects. Our aim was to evaluate the clinical relevance of OMBC in pulmonary metastasectomy of recurrent breast cancer. We also investigated lung meta...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3111-7

    authors： Mimoto R,Kobayashi T,Imawari Y,Kamio M,Kato K,Nogi H,Toriumi Y,Hirooka S,Uchida K,Takeyama H

    更新日期：2014-09-01 00:00:00

  • A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.

    abstract：PURPOSE:This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer. PATIENTS AND METHODS:The study enrolled 155 women with pathologically confirmed and measurable metastatic adenocarcinoma of t...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1023/a:1021384318470

    authors： Loesch DM,Asmar L,Canfield VA,Parker GA,Hynes HE,Ellis PG,Ferri WA Jr,Robert NJ

    更新日期：2003-01-01 00:00:00

  • Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.

    abstract：PURPOSE:To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-008-0055-9

    authors： Dickler MN,Cobleigh MA,Miller KD,Klein PM,Winer EP

    更新日期：2009-05-01 00:00:00

  • Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors.

    abstract：:In breast cancer, the survival rate strongly depends on the number of lymph nodes involved. A drug with a specific inhibitory activity on lymph node and organ metastases would therefore be a candidate for adjuvant therapy after surgery. Prostacyclin and its stable analogues have been shown to interfere with certain st...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF01803791

    authors： Schneider MR,Schirner M,Lichtner RB,Graf H

    更新日期：1996-01-01 00:00:00

  • Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II.

    abstract：:Findings from epidemiologic studies of oxidative stress biomarkers and breast cancer have been mixed, although no studies have focused on estrogen receptor-negative (ER-) tumors which may be more strongly associated with oxidative stress. We examined prediagnostic plasma fluorescent oxidation products (FlOP), a global...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3861-5

    authors： Hirko KA,Fortner RT,Hankinson SE,Wu T,Eliassen AH

    更新日期：2016-07-01 00:00:00

  • Improved prognostication in small (pT1) breast cancers by image cytometry.

    abstract：:Feulgen-stained samples from 460 small (pT1) primary breast cancers were investigated by means of an image analysis system. Several DNA, morphometrical and textural parameters were evaluated for each patient, and the prognostic meaning of these parameters was then investigated by the Cox regression analysis. As progno...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00690188

    authors： Aubele M,Auer G,Falkmer U,Voss A,Rodenacker K,Rutquist LE,Höfler H

    更新日期：1995-01-01 00:00:00

  • Sensory changes after treatment of operable breast cancer.

    abstract：:A study has been conducted to compare the nature and severity of post-operative sensory changes (sensory loss, paraesthesiae, and pain) among patients with breast cancer treated by either modified radical mastectomy or a conservative procedure (tumourectomy, axillary clearance, iridium implant, and external radiothera...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805925

    authors： Karydas I,Fentiman IS,Habib F,Hayward JL

    更新日期：1986-01-01 00:00:00

  • Alcohol intake and mammographic density in postmenopausal Norwegian women.

    abstract：:Mammographic density is a strong risk factor for breast cancer. While alcohol intake has been associated with increased breast cancer risk, the association between alcohol consumption and mammographic density is not clear. We assessed the association between alcohol consumption and mammographic density among women who...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1812-8

    authors： Qureshi SA,Couto E,Hofvind S,Wu AH,Ursin G

    更新日期：2012-02-01 00:00:00

  • Amplifications of oncogene erbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction.

    abstract：:A new method of measuring gene copy number in small samples of DNA was used to measure amplification of the erbB-2 gene and of chromosome 20q in breast cancer. This method, termed 'differentially competitive polymerase chain reaction' (DC-PCR) combines the advantages of two other techniques for measuring amplification...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806816

    authors： Deng G,Yu M,Chen LC,Moore D,Kurisu W,Kallioniemi A,Waldman FM,Collins C,Smith HS

    更新日期：1996-01-01 00:00:00

  • Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial.

    abstract：:We studied the cost of follow-up of 472 breast cancer patients without distant metastasis after primary treatment in four different schedules in a randomized trial. The mean follow-up was 4.2 years. The four schedules differed in frequency of follow-up visits (every third or sixth month) and in intensity of diagnostic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-005-5199-2

    authors： Kokko R,Hakama M,Holli K

    更新日期：2005-10-01 00:00:00

  • Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer.

    abstract：:The growth hormone and insulin-like growth factor (IGF) axis plays an essential role in the growth and development of the mammary gland. IGF1 and IGF1 receptor (IGF1R) may also play a role in the early transformation of mammary cells. Using a nested case-control design, the association between IGF1R expression in norm...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1313-1

    authors： Tamimi RM,Colditz GA,Wang Y,Collins LC,Hu R,Rosner B,Irie HY,Connolly JL,Schnitt SJ

    更新日期：2011-07-01 00:00:00

  • Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells.

    abstract：:The polypeptide hormone prolactin (Prl), acting through its cell surface receptors, promotes growth and differentiation in normal and malignant breast cells. We demonstrate herein that two Prl-responsive cell lines, NOG-8 normal mouse mammary epithelial and T47D human breast cancer cells, respond to Prl by rapid and t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806209

    authors： Das R,Vonderhaar BK

    更新日期：1996-01-01 00:00:00

  • Polyamines metabolism and breast cancer: state of the art and perspectives.

    abstract：:Breast cancer (BC) is a common disease that generally occurs in women over the age of 50, and the risk is especially high for women over 60 years of age. One of the major BC therapeutic problems is that tumors initially responsive to chemotherapeutic approaches can progress to more aggressive forms poorly responsive t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-014-3156-7

    authors： Cervelli M,Pietropaoli S,Signore F,Amendola R,Mariottini P

    更新日期：2014-11-01 00:00:00

  • Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.

    abstract：:Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthracycline and a taxane in the adjuvant or metastatic setting. This pha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-014-2923-9

    authors： McIntyre K,O'Shaughnessy J,Schwartzberg L,Glück S,Berrak E,Song JX,Cox D,Vahdat LT

    更新日期：2014-07-01 00:00:00

  • Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.

    abstract：PURPOSE:Time to surgery (TTS) is a potentially modifiable factor associated with survival after breast cancer diagnosis and can serve as a proxy for quality of oncologic care coordination. We sought to determine whether factors associated with delays in TTS vary between patients who receive neoadjuvant systemic therapy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-06012-7

    authors： Prakash I,Thomas SM,Greenup RA,Plichta JK,Rosenberger LH,Hyslop T,Fayanju OM

    更新日期：2020-11-18 00:00:00

  • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.

    abstract：BACKGROUND:The phrase "high-risk for breast cancer" is used to identify various groups at elevated cancer risk, and the appropriate surveillance and risk-reducing strategies differ based on the etiology of risk. Here, we review the utility of patient-reported data to capture women with modifiable lifestyle risk factors...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4115-x

    authors： Rosenberger LH,Weber R,Sjoberg D,Vickers AJ,Mangino DA,Morrow M,Pilewskie ML

    更新日期：2017-04-01 00:00:00

  • Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.

    abstract：PURPOSE:Younger women diagnosed with breast cancer have poorer prognoses and higher mortality compared to older women. Young black women have higher incidence rates of breast cancer and more aggressive subtypes than women of other races/ethnicities. In this study, we examined recent trends and variations in breast canc...

    journal_title：Breast cancer research and treatment

    pub_type： 历史文章,杂志文章

    doi：10.1007/s10549-018-4699-9

    authors： Shoemaker ML,White MC,Wu M,Weir HK,Romieu I

    更新日期：2018-06-01 00:00:00